• Français

• Home
• About CQDM
  • Mission and Objectives
  • Areas of Activity
  • Business Model
  • Annual Report
  • Partners
  • Collaborators
  • Team
  • Structure and Governance
    • Board of Directors
    • Executive Committee
    • Strategic Orientation Committee
    • Explore Advisory Committee
• Competition and Funding
  • FOCUS Competition
    • General Information
    • Current Competition
    • Previous Competitions
  • EXPLORE Competition
    • General Information
    • Current Competition
    • Previous Competitions
  • CQDM/Alsace BioValley Joint Program
    • General Information
    • Current Competition
    • Previous Competitions
• Funded
  Projects
  • FOCUS Competition
  • EXPLORE Competition
  • CQDM/Alsace BioValley Joint Program
• Drug Meeting Ground
  • Forums of Exchange
  • The Most Important Contributions in Biomedical Research in Québec
• News
  • CQDM News
  • News of the Researchers and Companies Funded by CQDM
• Press
  Articles
• Contact

• Mission and Objectives
• Areas of Activity
• Business Model
• Annual Report
• Partners
• Collaborators
• Team
• Structure and Governance
  • Board of Directors
  • Executive Committee
  • Strategic Orientation Committee
  • Explore Advisory Committee

About CQDM

Team

 

• 

  Max Fehlmann, Ph.D., MBA
  President and Chief Executive Officer

   

  Max Fehlmann has over 25 years of R&D management and business development experience gained within public research organizations and several biopharmaceutical companies. With a doctorate in Biochemistry from Université Laval, a doctorate in Pharmacology from the Université de Nice and an executive MBA from the Université de Nice-Sophia Antipolis, Mr. Fehlmann began his career in research at the INSERM in France as the head of an immunology research unit and then went on to create a federal research institute within the Faculty of Medicine at the Université de Nice. Following a sabbatical year at Harvard, Mr. Fehlmann left the INSERM to establish Aster, a biotechnology company specialized in reproductive immunology and biology. He was simultaneously appointed a professor at the Faculty of Science in Nice to oversee the senior professional diploma in pharmacology. In 1996, Zambon Group (Milan, Italy) bought Aster and appointed Mr. Fehlmann Vice-President of R&D for Zambon Group with responsibility for all research activities in Italy, Switzerland, the United States and France. In 2003, he was appointed President and CEO of Chronogen in Montreal. Since March 2008, Max Fehlmann is President and CEO at CQDM, an industrial consortium that brings together all of Québec's stakeholders in drug research.

  Back to the team ››